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Aim: To investigate the effect of the presence of pneumonia on the success of noninvasive mechanical ventilation (NIMV) in chronic
obstructive pulmonary disease (COPD) cases with acute respiratory failure.
Materials and methods: Sixty patients admitted to the intensive care unit (ICU) due to COPD exacerbation were included. The patients
were divided into 2 groups as those with pneumonia (Group 1) and without pneumonia (Group 2). According to initial pH values, cases
were also divided into 3 subgroups based on pH values. C-reactive protein (CRP), APACHE II scores, requirement of endotracheal
intubation, mortality, and duration of ICU and hospital stay were also recorded.
Results: NIMV success was found to be 85.5% in Group 1 and 51.1% in Group 2. Endotracheal intubation rates were higher in Group 2
(P = 0.008). NIMV failure was 70.1% in Group 2 and 10% in Group 1 in patients with severe acidosis. The APACHE II scores and CRP
levels were significantly higher and independent risk factors in patients with NIMV failure (P < 0.002, P < 0.001). A significant difference
was not found between groups in terms of duration of hospital and ICU stays and mortality.
Conclusion: The presence of pneumonia in COPD cases is a factor that reduces NIMV success, but this does not affect mortality and
the duration of ICU and hospital stay.
Key words: Respiratory failure, community-acquired pneumonia, noninvasive mechanical ventilation, chronic obstructive pulmonary
disease

1. Introduction
Acute exacerbations are the most important cause of
morbidity and mortality in chronic obstructive pulmonary
disease (COPD) cases (1). Recurrent episodes (2 to 3
attacks per year) are frequently observed in the course of
COPD (1,2). Hypoxic and hypercapnic respiratory failure
may develop due to COPD exacerbation (3). Although
endotracheal intubation and mechanical ventilation
are life-saving procedures, dangerous complications
such as infection and mechanical trauma are common.
Noninvasive mechanical ventilation (NIMV) is an
alternative approach to prevent complications in patients
with respiratory failure. The advantages of NIMV are the
maintenance of airway defense mechanisms, enabling
to swallow and to speak, and the decreased sedation
requirement (4,5). The advantages of NIMV, such as
improvements in physiological parameters, respiration
pattern, and arterial blood gases (ABG) measurements
and decreases in complications, hospital stay, and
* Correspondence: drserdarakpinar@yahoo.com

mortality, were demonstrated in controlled studies (6).
Community-acquired pneumonia is a fatal infectious
disease that has high treatment costs, particularly in
elderly patients who have COPD, diabetes mellitus,
congestive heart failure, and kidney failure (7). COPD is
the most frequently observed (25%–50%) comorbidity in
patients admitted to the hospital due to pneumonia (8).
Although NIMV was found ineffective in the treatment of
lower respiratory tract infections, it was demonstrated to
reduce the intubation rate, intensive care unit (ICU) stay,
and 2-month mortality rate in subgroups with underlying
COPD (9–11). Particularly, a careful observation and the
administration of NIMV under proper circumstances can
be considered in pneumonia patients with underlying
COPD. The presence of pneumonia accompanying acute
COPD attacks that affect the achievement of NIMV is still
under research. In this study, we aimed to investigate the
effect of the presence of pneumonia on NIMV success in
COPD cases with acute respiratory failure.
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2. Materials and methods
After approval from the institutional review board and
patients, 60 COPD patients admitted to a respiratory
ICU due to acute hypercapnic respiratory failure between
March 2010 and March 2011 were included in this study.
Patients with previously diagnosed COPD according to
the Global Initiative for Chronic Obstructive Lung Disease
(GOLD) criteria and with any FEV1/FVC rate below 70%
in spirometry were included in the study.
Cases with 1 major criterion (>38 °C temperature,
coughing, presence of purulent secretion) or 2 minor
criteria (dyspnea, chest pain, pulmonary consolidation
findings in physical examination, leukocyte count >12,000/
mm3 or <4000/mm3) confirming pneumonia, along with a
newly formed infiltration in a chest X-ray, were considered
as pneumonia. Cases in which pneumonia was considered
to develop within 48 h after patient discharge from the
hospital or 48 h after admission to the hospital were
excluded (12). Cases were grouped as Group 1 (COPD
acute respiratory failure [ARF] without pneumonia) and
Group 2 (COPD ARF with pneumonia). In the case of an
acute COPD attack, NIMV was routinely applied to patients
based on general criteria (respiratory rate [RR] >25/min,
PaCO2 >45 mmHg, and pH <7.35). An acute attack was
defined by the presence of 1 or several symptoms such as
exacerbation in difficulty of breathing, purulent sputum
production, coughing, fever, or an altered mental state for
at least 24 h. Routine acute attack management included
subcutaneous heparin, antibiotics, and bronchodilators
(aerosolized salbutamol and ipratropium bromide,
intravenous theophylline, corticosteroids), with the
correction of electrolyte abnormalities started for all cases.
NIMV was performed using a standard-size oronasal
mask with BIPAP (BiPap® Vision, Respironics, USA).
Initially, the pressure-supported spontaneous mode
expiratory positive airway pressure (EPAP) was adjusted
to 5 cmH2O, and the inspiratory positive airway pressure
was adjusted to 12 cmH2O. As long as it was tolerated
by the patients and based on the changes in ABG, the
pressure was then gradually increased to 1–2 cmH2O. The
maximum inspiratory positive airway pressure (IPAP) was
20 cmH2O and the maximum EPAP was 8 cmH2O.
Age, sex, body mass index (BMI), FEV1, the presence
of an additional disease, serum CRP level, heart rate (HR),
RR, APACHE II score, and the ABG measurements at the
1st, 4th, and 24th hours and after ICU discharge were all
recorded. We also recorded complications, intubation
requirements, first-month mortality, and the duration of
ICU stay, hospital stay, and treatment.
Exclusion criteria were as follows: 1) respiratory and/
or cardiac arrest; 2) intense secretion; 3) agitation and lack
of cooperation; 4) unstable clinical condition (hypotensive
shock, cardiac ischemia); 5) trauma, burns, or anatomic
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disorders of the face that would prevent the mask from
being secured; and 6) impaired cough and swallow reflex.
These were all accepted as contraindications (13). The
failure of NIMV was decided in cases of 1 major or 2
minor criteria within the first hour of NIMV (3). Major
criteria were considered to be respiratory arrest, loss
of consciousness, psychomotor agitation necessitating
sedation, impaired hemodynamics (systolic blood pressure
<70 mmHg or >180 mmHg), and bradycardia (HR <50
beats/min). Minor criteria were a RR of >35/min that
was also higher compared to the rate recorded at the time
of initial presentation, arterial pH of <7.30 that was also
lower compared to the initial presentation, PaO2 being <45
mmHg despite oxygen support, and the absence of a cough
reflex that would clear secretions. In addition, patients
were divided into subgroups based on pH values as Group
A (pH <7.25), Group B (pH 7.25–7.30), and Group C (pH
≥7.30). Intubation and mortality rates were compared for
all groups.
2.1. Statistical analysis
Statistical analysis was performed using SPSS 16.0 (SPSS
Inc., USA) for Windows. The results were expressed as
mean ± standard deviation. In the comparison between
groups, the chi-square and t-tests were utilized. The
Mann–Whitney U test was applied in the comparison
between groups. The Friedman test was used to analyze
the differences within time. The Bonferroni correction
was administered when the differences within time were
significant. P-values of less than 0.05 were considered to be
statistically significant in all analyses.
3. Results
There was no statistically significant difference when
groups were compared in terms of age, sex, BMI,
accompanying diseases, FEV1 values during the stable
illness before acute attack, and ABG values obtained at the
time of admittance to the ICU. The RR, CRP levels, and
initial APACHE II scores were found to be significantly
higher in the group with pneumonia (P = 0.013, P = 0.007,
and P = 0.011) (Table 1).
NIMV was performed in all cases, and it was successful
for 85.5% of Group 1 and 51.1% of Group 2. When the
groups were compared in terms of endotracheal intubation
rate, it was significantly higher in Group 2 (P = 0.008)
(Table 2).
A significant difference was not observed between
the groups in terms of duration of ICU or hospital stay
and mortality rate (Table 2). However, a significant
improvement was found in both groups in terms of ABG,
and there were no significant differences between the
groups in terms of ABG parameters (Table 3). Intubation
and mortality rate were found to be 10% in Group 1A (the
COPD group, cases with pH of <7.25). These rates were
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Table 1. Demographic, clinical, and functional characteristics of patients with COPD and COPD with pneumonia.
COPD ARF
(n = 35)

COPD + pneumonia
(n=25)

P-value

Age (years)

69 ± 8

68 ± 9

0.79

Sex (female / male)

13 / 22

7 / 18

0.72

APACHE II score

18 ± 4

21 ± 4

0.011*

Respiratory rate (bpm)

28 ± 8

33 ± 6

0.013*

Body mass index

24 ± 3.9

24 ± 5

0.57

FEV1 (%)

38 ± 24

52 ±11

0.14

7±6

11 ± 6

0.007*

7.27 ± 0.05

7.27 ± 0.04

0.772

PaCO2 (mmHg)

76 ± 15

74 ± 17

0.599

PaO2 (mmHg)

61 ± 37

50 ± 16

0.454

PaO2 / FiO2

165 ± 94

120 ± 58

0.029

30 ± 8

29 ± 6

0.927

C-reactive protein (mg/L)
pH

HCO3 (mmol/L)
* P < 0.05 between the groups.

Table 2. Intubation requirement, duration of ICU and hospital stays, and mortality during noninvasive
mechanical ventilation in patients with COPD and COPD with pneumonia.
Group 1

Group 2

P-value

Intubation rate (% / n)

14.5 / 5

48.9 / 12

0.008*

Duration of ICU stay (days)

11 ± 8

12.5 ± 11

0.64

Duration of hospital stay (days)

21 ± 8

21 ± 14

0.38

Mortality (% / n)

11.4 / 4

28 / 7

0.17

*P < 0.05 between the groups.

Table 3. Arterial blood gas values in patients with COPD and COPD with pneumonia at admission, on the first day, and on their
discharge from the ICU.
Group 1

Group 2

P-value

Admission

First day

Discharge

Admission

First day

Discharge

7.27 ± 0.05

7.40 ± 0.05

7.37 ± 0.12

7.27 ± 0.04

7.38 ± 0.05

7.35 ± 0.13

0.68

PaCO2 (mmHg)

76 ± 15

56 ± 13

50 ± 11

74 ± 17

55 ± 12

67 ± 35

0.05

PaO2 (mmHg)

61 ± 37

77 ± 22

70 ± 15

50 ± 16

66 ± 22

68 ± 20

0.56

PaO2 / FiO2

165 ± 94

210 ± 64

194 ± 54

120 ± 58

160 ± 71

162 ± 67

0.03

30 ± 8

28 ± 8

27 ± 8

29 ± 6

31 ± 7

30 ± 8

0.37

pH

HCO3 (mmol/L)
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found to be higher in Group 2A (71.4% and 28.6%) (Table
4). The CRP level and APACHE II scores were found to
be significantly higher in groups with failed NIMV (P =
0.002, P = 0.001) (Table 5). APACHE II scores and CRP
levels were also found to be independent risk factors for
NIMV failure (odds ratio [OR] 1.21, 95% confidence
interval [CI] 1.03–1.42, and OR 1.18, 95% CI 1.03–1.35).
4. Discussion
In the present study, NIMV treatment was successful for
85.5% of patients in Group 1 and 51.1% in Group 2. The
rate of endotracheal intubation was higher in Group 2.
NIMV failure was found at 70.1% in Group 2 and 10% in
Group 1 in patients with severe acidosis. The APACHE II
scores and CRP levels were significantly higher in patients
with NIMV failure, whereas a significant difference was
not found between the groups in terms of the duration of
hospital and ICU stays and mortality.
Bacakoğlu et al. found that NIMV treatment was
successful in 63.0% of patients with respiratory failure
due to COPD exacerbations, whereas treatment failure
was observed in 20 (37%) patients (early failure in 11,
late failure in 9) (14). NIMV success is still under debate
in COPD cases with acute respiratory failure having
pneumonia. Study results are variable in terms of the
rates of mortality and endotracheal intubation in the
presence of pneumonia accompanying COPD. High
failure rates in NIMV in pneumonia-related ARF led to

disappointment. Failure rates of up to 66% have been
reported for NIMV in ARF cases with severe communityacquired pneumonia (15,16). NIMV was demonstrated
to reduce the endotracheal intubation rate, ICU stay, and
2-month mortality rates in only the group with underlying
COPD among patients with severe community-acquired
pneumonia (17). Zvezdin et al. reported pneumonia as
the leading cause among early deaths in their postmortem
analysis of 43 patients hospitalized due to COPD
exacerbations (18). According to Rello et al., intubation
and mortality rates were higher in pneumonia patients
with COPD (88%) when compared to cases without COPD
(30.1%) (19). In our study, the intubation and mortality
rates were found to be higher in COPD ARF patients with
pneumonia (48.9%) compared to the COPD ARF group
(28%). We found high intubation and mortality rates, but
they were lower than those of these other studies. These
results confirmed the variability of study results.
Lieberman et al. compared 23 cases of COPD
accompanied with pneumonia and 190 patients who had
acute COPD attacks due to other reasons. According to
their results, the intubation rate was 17%, the need for
ICU 26%, and the rate of mortality 13% in the group with
COPD with pneumonia (20). In our study, intubation and
mortality rates were higher than in the study of Lieberman
et al. The main reason for these results might be related to
the high number of patients who had severe acidosis in the
COPD pneumonia ARF group.

Table 4. Each group was divided into 3 subgroups as pH of <7.25, 7.25–7.30, and >7.30 based on the patients’ initial pH
values, intubation rate, and mortality.
Subgroups

Subgroups

1A

1B

1C

2A

2B

2C

< 7.25

7.25–7.30

7.30–7.35

< 7.25

7.25–7.30

7.30–7.35

10

13

12

7

11

7

Intubation % / n

10 / 1

23.1 / 3

8.3 / 1

71.4 / 5

36.4 / 4

42.9 / 3

Mortality % / n

10 / 1

15.4 / 2

8.3 / 1

28.6 / 2

18.2 / 2

42.9 / 3

pH
n

Table 5. CRP level and APACHE II score in patients with success and failure with NIMV.
NIMV success (n = 43)

NIMV failure
(n = 17)

P-value

CRP (mg/L)

7.5 ± 6.4

12.9 ± 5.2

0.002*

APACHE II score

18.3 ± 4.1

22.4 ± 4.2

0.001*

CRP: C-reactive protein. *P < 0.05 between the groups.
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Güngör et al. concluded that the presence of pneumonia
did not influence the duration of ICU stay in COPD
patients with ARF (21). Our results were similar in this
study in terms of duration of ICU stay and hospital stay.
Therefore, the presence of pneumonia is not a negative
factor in performing NIMV in COPD cases.
It has been reported in previous studies that failure of
NIMV occurred at rates ranging from 52% to 62% in COPD
cases with severe respiratory acidosis (pH of <7.25) (17,22,23).
Even though the risk of failure in severe cases is high, NIMV,
if endotracheal intubation is not obligatory, is recommended
to protect the airways and to prevent a loss of consciousness
and difficulty in breathing in ARF due to COPD (17,22–
24). Despite all these results, the number of randomized
controlled studies on patients with COPD plus pneumonia
with severe respiratory acidosis is quite low. Scala et al.
performed noninvasive or invasive mechanical ventilation in
a group of COPD patients who had an attack period with
severe acidosis. According to their results, those who had
noninvasive ventilation had a lower duration of hospital stay
and mechanical ventilation and lower complication rates,
and a difference was not observed between the 2 groups in
terms of 1-year mortality and hospital mortality. They also
reported the failure rate of NIMV as 35% (25). In our study,
noninvasive ventilation failure in COPD pneumonia cases
with severe respiratory acidosis (pH <7.25) was found to be
71.4%, and 1-month mortality was 28%. In ARF cases with
COPD exacerbation due to other reasons, the intubation rate
was found to be 10% and mortality rate to be 12%. In COPD
pneumonia cases with ARF, NIMV success was quite low in
patients with pH values below 7.25, and there is a need to
observe randomized controlled studies that have a greater
number of cases.
APACHE II is a frequently used scoring system
in determining the severity of a disease and has a

high reliability (26). Amrossino et al. demonstrated
significantly higher APACHE II values in the group in
which NIMV failed compared to those who had success
with NIMV (the mean APACHE II score was 24 in the
failed group and 18 in the successful group) (27). Soo
Hoo et al. measured the mean APACHE II scores as 21
± 4 in the failed group and 15 ± 4 in the successful group
(28). Confalonieri et al. reported good indicators for
evaluating the prospects of success through 4 individual
parameters, which were APACHE II scores, pH, RR,
and the Glasgow Coma Scale (29). Kaya et al. evaluated
95 patients with acute hypercapnic respiratory failure
and found that APACHE II scores and high CRP levels
were predictable factors in NIMV failure (30). In our
study, APACHE II scores and CRP levels were found to
be significantly higher in the group with NIMV failure
(the mean APACHE II scores were 22 ± 4 in the failed
group and 18 ± 4 in the successful group). When both
groups were compared, APACHE II scores and CRP
levels were established as significantly higher in the
group with COPD plus pneumonia. Moreover, both of
these parameters were found as independent risk factors
for NIMV success. These results show that in cases with
high APACHE II scores and CRP levels, the possibility of
failure was also observed to be strong.
In conclusion, the presence of pneumonia in COPD
cases with acute respiratory failure is a factor reducing the
success rate of NIMV, but it does not affect mortality or
the duration of ICU and hospital stay. High APACHE II
scores and serum CRP levels independently correlate with
NIMV failure. However, the rate of NIMV failure is very
high in COPD pneumonia cases with severe acidosis, and
therefore NIMV should be an alternative in these cases.
Detailed studies with a high number of severe acidosis
cases are necessary to confirm these results.
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